Look back at pharma news in the week to June 4, 2021
By Barbara Obstoj-Cardwell. Editor
Last week’s deal-making news featured US biotech giant Amgen announcing a licensing agreement with Japan’s Kyowa Kirin to develop the latter’s KHK4083 for atopic dermatitis, for a potential $1.2 billion. Also, Australian drug developer Immutep signed a licensing deal with Germany’s Merck KGaA for its PD-1 inhibitor eftilagimod alfa, which also attracted attention at the ASCO meeting. On the regulatory front, Ireland’s Alkermes finally gained US Food and Drug Administration approval for its Lybalvi (olanzapine and samidorphan) for the treatment of schizophrenia and bipolar 1 disorder. Germany’s MorphoSys announced it is acquiring US firm Constellation Pharmaceuticals along with its lead candidates pelabresib and CPI-0209, which are hematological and cancer treatments, respectively, for a total of $1.7 billion.
Amgen follows Sanofi into a new dermatitis mechanism
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze